Enliven Therapeutics, Inc.
NASDAQ:ELVNBiotechnology
-$0.12 today
- Market cap
- $3.30B
- Beta
- 0.40
- P/E (TTM)
- -28.4
- EPS (TTM)
- -$1.57
Volume 0.75M
Average 1.35M
ELVN Total Current Liabilities
All obligations due within one year.
Enliven Therapeutics, Inc.NASDAQ: ELVN
Total Current Liabilities · Q3 FY2026 · quarter ended Sep 2026
Total current liabilities rises 32.9% from a year ago
Total current liabilities stood at $19.47M at the end of Q3 FY2026, up 32.9% from a year earlier and up 37.5% from the prior quarter. Over 3 fiscal years it compounded at +19.5% a year.
Context
- Total current liabilities amounted to 2.2% of total assets at the end of Q3 FY2026, down 0.8 pp from a year earlier.
- Total current liabilities increased in 2 of the last 3 fiscal years.
What to watch
Whether total current liabilities keeps rising in the next quarterly balance sheet after a +32.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 16.57M USD
- Year-over-year change
- +4.1%
- 4-year CAGR
- +30.3%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 16.57M | +4.1% |
| FY2024 | 2024-12-31 | 15.92M | -38.5% |
| FY2023 | 2023-12-31 | 25.89M | +166.5% |
| FY2022 | 2022-12-31 | 9.72M | +68.9% |
| FY2021 | 2021-12-31 | 5.75M | — |
Total Current Liabilities vs competitors
How ELVN compares with its peers on the latest reported figures
- ELVN's Sep 2026 total current liabilities of $19.47M is the 9th highest of the 11 companies compared; the peer median is $68.49M.
- Its year-over-year change of +32.9% is the 5th highest of 11, against a peer median of +29.6%.
- Total current liabilities amounts to 2.2% of total assets for ELVN, versus a peer median of 8.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $1.31B | +2.6% | +9.4% | 16.7% | |
| Jul 2026 | $361.93M | +7.7% | +7.7% | 14.5% | |
| Jun 2026 | $354.06M | +91.9% | +67.3% | 8.2% | |
| Jun 2026 | $86.76M | +30.7% | +84.2% | 11.7% | |
| Mar 2026 | $86.17M | -8.9% | +60.5% | 18.2% | |
| Jun 2026 | $50.8M | +56.2% | -26.2% | 5.3% | |
| Mar 2026 | $35.15M | +28.5% | +18.8% | 8.7% | |
| Mar 2026 | $25M | +93.0% | +45.9% | 7.2% | |
| Sep 2026 | $19.47M | +32.9% | +19.5% | 2.2% | |
| Mar 2026 | $19.26M | +35.2% | +47.0% | 4.7% | |
| Mar 2026 | $17.77M | +0.9% | +9.9% | 4.1% | |
| Peer median (excluding ELVN) | $68.49M | +29.6% | +32.3% | 8.5% | |
Competitors are the stored peer set for ELVN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 110.02M | 75.54M | 100.14M | 124.12M | 98.9M |
| Short-term Investments | 0 | 0 | 153.01M | 189.32M | 363.73M |
| Net Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 2.22M | 10.05M | 4.69M | 12.26M |
| Total Current Assets | 110.67M | 77.75M | 266.15M | 318.13M | 474.88M |
| Property, Plant & Equipment (Net) | 954K | 1.52M | 1.06M | 458K | 417K |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 54K | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 1.71M | 3.98M | 4.65M | 7.18M | 873K |
| Total Non-current Assets | 2.66M | 5.55M | 5.72M | 7.63M | 1.29M |
| Total Assets | 113.33M | 83.3M | 271.87M | 325.76M | 476.17M |
| Account Payables | 2.52M | 3.44M | 532K | 1.34M | 2.16M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 5.51M | 0 | 0 | 0 |
| Other Current Liabilities | 233K | 320K | 10.36M | 204K | 4.65M |
| Total Current Liabilities | 5.75M | 9.72M | 25.89M | 15.92M | 16.57M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 108K |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 714K | 150.41M | 67K | 0 | 0 |
| Total Non-current Liabilities | 714K | 150.41M | 67K | 0 | 108K |
| Total Liabilities | 6.47M | 160.12M | 25.96M | 15.92M | 16.68M |
| Common Stock | 1K | 1K | 41K | 49K | 59K |
| Retained Earnings | (45.2M) | (82.86M) | (154.45M) | (243.47M) | (347.17M) |
| Accumulated OCI | 0 | (149.75K) | 141K | 55K | 334K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 106.86M | (76.83M) | 245.91M | 309.85M | 459.6M |
| Total Debt | 159K | 323K | 335K | 0 | 399K |
| Net Debt | (109.87M) | (75.21M) | (99.81M) | (124.12M) | (98.5M) |
Enliven Therapeutics, Inc.
NASDAQ:ELVN
Intrinsic Alpha fair value
Locked
Current Price
$44.89
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.